New osteoporosis drug copycat tested in healthy volunteers
NCT ID NCT07384104
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called SAL023 works like the approved osteoporosis medicine Evenity. It involves 118 healthy Chinese adults who get a single dose of either SAL023 or Evenity. The goal is to compare how the body processes the drug, its safety, and any immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Hospital of Anhui Medical University Clinical Pharmacology Research Center
Hefei, Anhui, 230601, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bone health blind spot: do spinal cord injury patients know their fracture risk?
- Heavy weights vs. light weights: which builds better bones?
- Could common statins be a surprise weapon against brittle bones?
- Saliva may reveal hidden links between bone loss and tooth decay
- New program aims to cut hip fractures in nursing homes
- New model aims to predict jaw bone disease before it strikes